Abstract

The PAM intervention is a behavioural intervention to support adherence to anti-hypertensive medications and therefore to lower blood pressure. This feasibility trial recruited 101 nonadherent patients (54% male, mean age 65.8 years) with hypertension and high blood pressure from nine general practices in the UK. The trial had 15.5% uptake and 7.9% attrition rate. Patients were randomly allocated to two groups: the intervention group (n = 61) received the PAM intervention as an adjunct to usual care; the control group (n = 40) received usual care only. At 3 months, biochemically validated medication adherence was improved by 20% (95% CI 3–36%) in the intervention than control, and systolic blood pressure was reduced by 9.16 mmHg (95% CI 5.69–12.64) in intervention than control. Improvements in medication adherence and reductions in blood pressure suggested potential intervention effectiveness. For a subsample of patients, improvements in medication adherence and reductions in full lipid profile (cholesterol 1.39 mmol/mol 95% CI 0.64–1.40) and in glycated haemoglobin (3.08 mmol/mol, 95% CI 0.42–5.73) favoured the intervention. A larger trial will obtain rigorous evidence about the potential clinical effectiveness and cost-effectiveness of the intervention.

Trial registration Trial date of first registration 28/01/2019. ISRCTN74504989. https://doi.org/10.1186/ISRCTN74504989.

Details

Title
The feasibility of the PAM intervention to support treatment-adherence in people with hypertension in primary care: a randomised clinical controlled trial
Author
Kassavou Aikaterini 1 ; Mirzaei Venus 1 ; Shpendi Sonia 1 ; Brimicombe, James 1 ; Chauhan Jagmohan 2 ; Bhattacharya Debi 3 ; Naughton, Felix 4 ; Hardeman, Wendy 4 ; Eborall, Helen 5 ; Miranda, Van Emmenis 1 ; De Simoni Anna 6 ; Takhar Amrit 7 ; Gupta, Pankaj 8 ; Patel, Prashanth 8 ; Mascolo, Cecilia 9 ; Prevost, Andrew Toby 10 ; Morris, Stephen 1 ; Griffin, Simon 1 ; McManus, Richard J 11 ; Mant, Jonathan 1 ; Sutton, Stephen 1 

 University of Cambridge, Department of Public Health and Primary Care, The Primary Care Unit, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934) 
 University of Cambridge, Department of Computer Science and Technology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); University of Southampton, School of Electronics and Computer Science, Southampton, UK (GRID:grid.5491.9) (ISNI:0000 0004 1936 9297) 
 University of East Anglia, School of Pharmacy, Norwich, UK (GRID:grid.8273.e) (ISNI:0000 0001 1092 7967) 
 University of East Anglia, School of Health Sciences, Norwich, UK (GRID:grid.8273.e) (ISNI:0000 0001 1092 7967) 
 Usher Institute, University of Edinburgh, Edinburgh, UK (GRID:grid.4305.2) (ISNI:0000 0004 1936 7988) 
 Queen Mary University of London, Institute of Population Health Sciences, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133) 
 Cambridgeshire and Peterborough Clinical Commissioning Group, Cambridge, UK (GRID:grid.4868.2) 
 University Hospitals of Leicester NHS Trust, Department of Metabolic Medicine and Chemical Pathology, Leicester, UK (GRID:grid.269014.8) (ISNI:0000 0001 0435 9078) 
 University of Cambridge, Department of Computer Science and Technology, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934) 
10  King’s College London, Nightingale-Saunders Clinical Trials and Epidemiology Unit, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764) 
11  University of Oxford, Nuffield Department of Primary Care Health Sciences, Oxford, UK (GRID:grid.4991.5) (ISNI:0000 0004 1936 8948) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2518557869
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.